Advances in monoclonal antibody therapy for multiple myeloma

At the Myeloma 2015 meeting, Dr Joseph Mikhael (Mayo Clinic, Scottsdale, AZ) discusses the development of monoclonal antibodies (mAbs), including anti-CD38 mAbs, SAR650984 and daratumumab, and anti-SLAMF7 mAb, elotuzumab, for the treatment of multiple myeloma. Clinical results to date suggest these monoclonal antibodies are likely to operate synergistically with other therapies.

Share this video